Lung Cancer
Conditions
Brief summary
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Detailed description
\[Sample acquisition\] * Informed consent is waived for those who agree to donate samples left over from other clinical trials or acquired for other purposes to be used for other research by the sign to master agreement in advance. * The study will be conducted based on the purposes indicated in the master agreement signed by tissue donator \[Clinical data acquisition\] * Baseline demographics: Sex, Birth date, expire date (last follow-up date for the survivals) * Lung cancer treatment history: diagnosed date, treatment history (surgery, radiation therapy, chemotherapy, immunotherapy treatment history, and responses), general performance, metastatic sites * Lung cancer histologic information: pathology, histologic subtype, EGFR mutation profile, ALK-rearrangement result
Interventions
None listed
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. aged above or equal to 18 2. Histologically confirmed lung cancer patients 3. Patient treated with immune checkpoint inhibitor Exculsion Criteria: NA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| List of biomarkers | Baseline | Neoantigen, tumor mutation burden, MHC compatibility, T-cell receptor and associated immune gene signature (IFN-r, interferons such as IL-2 and interleukin family), T-cell subset (T cell surface marker such as CD4+, CD7+, CD8+, CD16, CD34+, CD38+, CD56+, etc.), PD-1/PD-L1 expression, etc. |
Countries
South Korea
Contacts
CONTACTSe-hoon Lee, MD
CONTACTJinhee Seo
STUDY_CHAIRSe-hoon Lee, MD
Samsung Medical Center
Outcome results
None listed